CAPROCK Group Inc. Sells 2,375 Shares of Eli Lilly And Co (LLY)

CAPROCK Group Inc. cut its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 25.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,110 shares of the company’s stock after selling 2,375 shares during the period. CAPROCK Group Inc.’s holdings in Eli Lilly And Co were worth $923,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the stock. Vanguard Group Inc. boosted its position in Eli Lilly And Co by 0.7% during the 3rd quarter. Vanguard Group Inc. now owns 74,132,985 shares of the company’s stock worth $7,955,211,000 after buying an additional 511,752 shares during the period. Vanguard Group Inc boosted its position in Eli Lilly And Co by 0.7% during the 3rd quarter. Vanguard Group Inc now owns 74,132,985 shares of the company’s stock worth $7,955,211,000 after buying an additional 511,752 shares during the period. BlackRock Inc. boosted its position in Eli Lilly And Co by 3.0% during the 4th quarter. BlackRock Inc. now owns 68,956,519 shares of the company’s stock worth $7,979,649,000 after buying an additional 2,030,845 shares during the period. Oregon Public Employees Retirement Fund boosted its position in Eli Lilly And Co by 17,720.8% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 42,420,406 shares of the company’s stock worth $367,000 after buying an additional 42,182,367 shares during the period. Finally, FMR LLC lifted its position in shares of Eli Lilly And Co by 83.9% in the 4th quarter. FMR LLC now owns 13,687,081 shares of the company’s stock worth $1,583,870,000 after purchasing an additional 6,242,865 shares during the period. Institutional investors and hedge funds own 79.58% of the company’s stock.

Eli Lilly And Co stock opened at $124.08 on Tuesday. The company has a debt-to-equity ratio of 1.07, a quick ratio of 1.38 and a current ratio of 1.73. Eli Lilly And Co has a 12-month low of $77.09 and a 12-month high of $132.13. The firm has a market cap of $129.63 billion, a P/E ratio of 22.36, a P/E/G ratio of 2.37 and a beta of 0.33.

Eli Lilly And Co (NYSE:LLY) last released its earnings results on Wednesday, February 6th. The company reported $1.33 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.36 by ($0.03). Eli Lilly And Co had a net margin of 13.16% and a return on equity of 44.66%. The company had revenue of $6.44 billion for the quarter, compared to analyst estimates of $6.28 billion. During the same quarter in the previous year, the firm earned $1.14 EPS. The firm’s revenue was up 4.5% on a year-over-year basis. On average, equities research analysts expect that Eli Lilly And Co will post 5.66 EPS for the current fiscal year.

In related news, SVP Stephen F. Fry sold 14,847 shares of the business’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $123.16, for a total transaction of $1,828,556.52. Following the transaction, the senior vice president now owns 109,663 shares in the company, valued at approximately $13,506,095.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 205,000 shares of the business’s stock in a transaction on Tuesday, March 26th. The shares were sold at an average price of $131.41, for a total transaction of $26,939,050.00. Following the transaction, the insider now owns 116,814,018 shares in the company, valued at approximately $15,350,530,105.38. The disclosure for this sale can be found here. Insiders have sold a total of 989,224 shares of company stock worth $123,587,253 in the last quarter. 0.11% of the stock is owned by corporate insiders.

A number of research analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $142.00 price target on the stock in a research report on Wednesday, April 10th. Barclays restated a “buy” rating and issued a $140.00 price target on shares of Eli Lilly And Co in a research report on Sunday. Bank of America set a $129.00 price target on shares of Eli Lilly And Co and gave the stock a “hold” rating in a research report on Thursday, March 21st. Citigroup set a $124.00 price target on shares of Eli Lilly And Co and gave the stock a “hold” rating in a research report on Tuesday, February 26th. Finally, Cantor Fitzgerald restated a “buy” rating on shares of Eli Lilly And Co in a research report on Monday, February 4th. Ten research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $118.02.

COPYRIGHT VIOLATION WARNING: “CAPROCK Group Inc. Sells 2,375 Shares of Eli Lilly And Co (LLY)” was first published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.thelincolnianonline.com/2019/04/16/caprock-group-inc-sells-2375-shares-of-eli-lilly-and-co-lly.html.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Further Reading: How to Invest in an Index Fund

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.